AVEO Pharmaceuticals (NASDAQ:AVEO)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research report issued to clients and investors on Monday. They presently have a $9.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target would indicate a potential upside of 356.85% from the company’s current price.

The analysts wrote, “We maintain our Buy rating on AVEO and our 12-month price target of $9.00 per share. We derive our price target based on a risk-adjusted NPV analysis of projected tivozanib and ficlatuzumab revenues through 2030 assuming a 12.5% discount rate and 3% terminal growth rate. We derive an rNPV of $1.5B for the products and add in cash and cash equivalents of $18M to arrive at a 12-month price target of $9.16 per diluted share, which we round to $9.00.””

Several other research firms also recently commented on AVEO. B. Riley assumed coverage on AVEO Pharmaceuticals in a research report on Tuesday, January 8th. They issued a “buy” rating and a $5.00 target price on the stock. National Securities downgraded AVEO Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Tuesday, November 6th. FBR & Co set a $3.00 target price on AVEO Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, December 20th. Robert W. Baird assumed coverage on AVEO Pharmaceuticals in a research report on Thursday, January 3rd. They issued an “outperform” rating and a $3.00 target price on the stock. Finally, Zacks Investment Research downgraded AVEO Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 23rd. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $4.45.

AVEO opened at $1.97 on Monday. AVEO Pharmaceuticals has a 52-week low of $1.40 and a 52-week high of $3.59. The stock has a market cap of $265.73 million, a P/E ratio of -12.31 and a beta of 2.14.

AVEO Pharmaceuticals (NASDAQ:AVEO) last released its earnings results on Friday, November 9th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.01. The company had revenue of $2.47 million for the quarter, compared to the consensus estimate of $0.68 million. On average, analysts expect that AVEO Pharmaceuticals will post -0.25 EPS for the current fiscal year.

In related news, Director Anthony B. Evnin sold 1,147,068 shares of the stock in a transaction that occurred on Friday, November 16th. The stock was sold at an average price of $1.87, for a total transaction of $2,145,017.16. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Peter W. Sonsini purchased 24,500 shares of AVEO Pharmaceuticals stock in a transaction that occurred on Wednesday, November 28th. The shares were bought at an average cost of $1.99 per share, for a total transaction of $48,755.00. The disclosure for this purchase can be found here. Insiders bought 2,358,709 shares of company stock worth $4,272,673 in the last ninety days. 4.40% of the stock is owned by company insiders.

Large investors have recently modified their holdings of the stock. Vanguard Group Inc raised its stake in shares of AVEO Pharmaceuticals by 1.5% during the third quarter. Vanguard Group Inc now owns 5,066,360 shares of the biopharmaceutical company’s stock valued at $16,770,000 after acquiring an additional 73,519 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of AVEO Pharmaceuticals by 1.5% during the third quarter. Vanguard Group Inc. now owns 5,066,360 shares of the biopharmaceutical company’s stock valued at $16,770,000 after acquiring an additional 73,519 shares during the last quarter. Teachers Advisors LLC raised its stake in shares of AVEO Pharmaceuticals by 75.8% during the third quarter. Teachers Advisors LLC now owns 227,334 shares of the biopharmaceutical company’s stock valued at $752,000 after acquiring an additional 98,009 shares during the last quarter. MetLife Investment Advisors LLC bought a new position in shares of AVEO Pharmaceuticals during the third quarter valued at about $275,000. Finally, X Square Capital LLC raised its stake in shares of AVEO Pharmaceuticals by 18.9% during the third quarter. X Square Capital LLC now owns 284,425 shares of the biopharmaceutical company’s stock valued at $942,000 after acquiring an additional 45,190 shares during the last quarter. 40.11% of the stock is currently owned by institutional investors and hedge funds.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).

Featured Article: How to read a candlestick chart

Analyst Recommendations for AVEO Pharmaceuticals (NASDAQ:AVEO)

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.